The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis-Reference-Cited by-同舟云学术

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Published:2013-05-28 Issue:10 Volume:98 Page:1510-1516
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Nicolini F. E.,Ibrahim A. R.,Soverini S.,Martinelli G.,Muller M. C.,Hochhaus A.,Dufva I. H.,Kim D.-W.,Cortes J.,Mauro M. J.,Chuah C.,Labussiere H.,Morisset S.,Roche-Lestienne C.,Lippert E.,Hayette S.,Peter S.,Zhou W.,Maguer-Satta V.,Michallet M.,Goldman J.,Apperley J. F.,Mahon F.-X.,Marin D.,Etienne G.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation;Clinical Pharmacokinetics;2024-09-07

2. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation;Leukemia;2024-07-04

3. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results;Leukemia;2024-05-16

4. A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience;Indian Journal of Hematology and Blood Transfusion;2024-04-23

5. Utility of T315I mutation in Egyptian patients with chronic myeloid leukemia;Egyptian Journal of Basic and Applied Sciences;2024-02-26